Editorial

Neurological complications and COVID-19: A literature review
Aslam Pathan
Editor-in-Chief, NeuroPharmac Journal

ARTICLE INFO

Article history:
Received 20 April 2021
Accepted 24 April 2021
Available online
30 April 2021

Keywords:
COVID-19
Neurological complications

ABSTRACT

Reported studies from many works of literature state that coronavirus disease 2019 (COVID-19) affects the central nervous system and peripheral nervous system leads to many neurological indications including headache, dizziness, impaired consciousness, acute cerebrovascular disease, epilepsy, hyposmia/anosmia, hypogeusia/ageusia, muscle pain, altered mental status, and Guillain-Barre syndrome.

This review article summarized the reported neurological complications in coronavirus disease 2019 patients worldwide. Healthcare workers should aware of a wide range of neurological symptoms for the early diagnosis and management of the cases.

The pandemic of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already affected more than 2.7 million people and caused more than 3,021,397 deaths worldwide.1 According to the reported studies, more than 35% of COVID-19 patients develop neurological symptoms. Some COVID-19 patients may present neurologic symptoms as the initial presentations of the disease.2 One study conducted on 214 hospitalized patients in Wuhan, China concludes that compared with non-severe patients with COVID-19, severe patients commonly had neurologic symptoms manifested as acute cerebrovascular diseases (5.7%), consciousness impairment (14.8%), skeletal muscle symptoms (19.3%), anosmia in 11 (5.1%) patients and ageusia in 12 (5.6%) patients.3,4

Viral meningoencephalitis with the presence of SARS-CoV-2 in cerebrospinal fluid by viral genome sequencing has been reported in patients in China5 and Japan.6 In one reported study in the USA, a woman aged between 50 and 60 years developed COVID-19 and altered mental status. Brain magnetic resonance imaging (MRI) on this patient showed bilateral hemorrhagic rim-enhancing lesions within thalami, medial temporal lobes, and subinsular regions characteristic of acute hemorrhagic necrotizing encephalopathy.7

Findings from the Spanish Society of Neurology indicate that a total of 233 cases were submitted, including 74 different combinations of
manifestations. The most frequently reported were stroke (27%), neuromuscular symptoms (23.6%), altered mental status (23.6%), anosmia (17.6%), headache (12.9%), and seizures (11.6%). The mean age of patients was 61.1 years, with 42.1% being women; a higher proportion of women was recorded among patients with altered mental status, anosmia, and headache.8

One reported study from the USA indicates the cervical spinal cord infarction associated with coronavirus infectious disease (COVID-19) in the 31-year-old male patient.9

The global response to the pandemic indicates that healthcare authorities, neurologists and government authorities, and scientists should create databases of neurological complications related to COVID-19. These databases will also contain peer-reviewed publications of the reported neurological complications of the pandemic. This effort should help develop an understanding of the neurological impact of COVID-19.

The Spanish Neurological Society implemented a registry of neurological manifestations in patients with confirmed COVID-19. We appreciate this initiative and hope to expand these efforts globally to define the neurological involvement in COVID-19, which will help healthcare workers for the early diagnosis and management of the cases.

Cite this article:

References:


Copyright © 2021 NeuroPharmac J. This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License.